Drug
Linperlisib clinical trials
Also written YY-20394.
- studies test it
- 22
- open now
- 10
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the linperlisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 13
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 10
Shanghai YingLi Pharmaceutical Co. Ltd. (12) · Institute of Hematology & Blood Diseases Hospital, China (4) · Ruijin Hospital (2) · Sun Yat-sen University (1) · Peking Union Medical College Hospital (1) · Yanyan Liu (1) · Beijing Tongren Hospital (1)
Often tested with
Tested in the same studies.
Tucidinostat (3) · Zeprumetostat (2) · Camrelizumab (2) · Golidocitinib (1) · Pegaspargase (1) · Azacitidine (1) · Dasatinib (1) · Apatinib (1)
Studies
Open first, then newest update. How each study uses linperlisib is read from its arms, and is right about nine times in ten.
Testing it · 22
- Linperlisib Combined With Chidamide in Patients With PTCLRecruitingPhase 1/2Yanyan LiuNCT06421948Written as Linperlisib and chidamide
- Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingPhase 1/2Ruijin HospitalNCT07209163Written as Linperlisib
- Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07139353Written as Linperlisib
- Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06224257Written as Linperlisib
- Linperlisib in the Treatment of aPRCANot yet recruitingPhase 2Peking Union Medical College HospitalNCT07031115Written as Linperlisib
- Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT06712173Written as linperlisib and SHR2554
- A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell LymphomaNot yet recruitingPhase 2/3Shanghai YingLi Pharmaceutical Co. Ltd.NCT06548347Written as Linperlisib
- Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingPhase 1/2Beijing Tongren HospitalNCT06376721Written as Linperlisib
- A National Multicenter, Real-world Study of Linperlisib in the Treatment of LymphomaNot yet recruitingPhase 4Shanghai YingLi Pharmaceutical Co. Ltd.NCT06343935Written as Linperlisib
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingPhase 1/2Ruijin HospitalNCT05559008Written as Linperlisib
- PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of TherapyTerminatedPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT05676697Written as Linperlisib
- A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic MalignanciesCompletedPhase 1Shanghai YingLi Pharmaceutical Co. Ltd.NCT04279405Written as YY-20394
- Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaCompletedPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT05676710Written as Linperlisib
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownPhase 2Shanghai YingLi Pharmaceutical Co. Ltd.NCT05274997Written as YY-20394
- A Study of Linperlisib Combination With Camrelizumab in Patients With Solid TumorStatus unknownPhase 1Shanghai YingLi Pharmaceutical Co. Ltd.NCT05429398Written as Linperlisib Tablet
- A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownPhase 1Shanghai YingLi Pharmaceutical Co. Ltd.NCT04108325Written as YY-20394
- A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownPhase 2Shanghai YingLi Pharmaceutical Co. Ltd.NCT04705090Written as YY-20394 treatment
- YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownPhase 1/2Shanghai YingLi Pharmaceutical Co. Ltd.NCT04500561Written as YY-20394
- A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's LymphomaStatus unknownPhase 2Shanghai YingLi Pharmaceutical Co. Ltd.NCT04370405Written as YY-20394
- A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular LymphomaStatus unknownPhase 2Shanghai YingLi Pharmaceutical Co. Ltd.NCT04379167Written as YY-20394
See all 22 studies that test linperlisib →
Given in every arm · 1 — linperlisib is usual care beside what is tested
Codes
What other systems call linperlisib · ClinicalTrials.gg INT014157
- UNII (FDA) 05HYK3CV9NLINPERLISIBConfirmed FDA, Wikidata
- Wikidata Q105337368linperlisibConfirmed FDA, Wikidata
- NCI Thesaurus C158508LinperlisibOne source FDA
- DrugBank DB17235One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 05HYK3CV9N | LINPERLISIB | Confirmed FDA, Wikidata |
| Wikidata | Q105337368 | linperlisib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C158508 | Linperlisib | One source FDA |
| DrugBank | DB17235 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.